Aerosolized amphotericin B lipid complex as adjunctive treatment for fungal lung infection in patients with cancer-related immunosuppression and recipients of hematopoietic stem cell transplantation

Pharmacotherapy

Volumn 33, Issue 10, 2013, Pages 1035-1043

  Safdar, Amar ^a,b   Rodriguez, Gilhen H ^a  

^a UNIVERSITY OF TEXAS   (United States)

^b NEW YORK UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

aerosolized amphotericin B lipid complex; cancer; hematopoietic transplantation; infections; lung disease; neutropenia; refractory fungal infection

Indexed keywords

AMPHOTERICIN B LIPID COMPLEX; CORTICOSTEROID; ECHINOCANDIN; POSACONAZOLE; VORICONAZOLE;

ACUTE LEUKEMIA; ADULT; AEROSOL; AGED; ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; ARTICLE; ASPERGILLUS; BASIDIOMYCETES; BRONCHOSPASM; CLINICAL ARTICLE; CLINICAL EFFECTIVENESS; COHORT ANALYSIS; COUGHING; DRUG EFFICACY; DRUG MEGADOSE; DRUG RESPONSE; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; FEMALE; FUSARIUM; HUMAN; IMMUNE DEFICIENCY; LUNG MYCOSIS; MALE; NAUSEA AND VOMITING; NEUTROPENIA; RHIZOMUCOR; SCEDOSPORIUM PROLIFICANS; THORAX PAIN; TREATMENT DURATION; TREATMENT INDICATION; TREATMENT OUTCOME;

AEROSOLIZED AMPHOTERICIN B LIPID COMPLEX; CANCER; HEMATOPOIETIC TRANSPLANTATION; INFECTIONS; LUNG DISEASE; NEUTROPENIA; REFRACTORY FUNGAL INFECTION;

ADULT; AGED; AMPHOTERICIN B; ANTIFUNGAL AGENTS; FEMALE; GLUCOCORTICOIDS; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; IMMUNOCOMPROMISED HOST; LUNG DISEASES, FUNGAL; MALE; MIDDLE AGED; NEOPLASMS; NEUTROPENIA; RETROSPECTIVE STUDIES; SEVERITY OF ILLNESS INDEX; YOUNG ADULT;

EID: 84900866886     PISSN: 02770008     EISSN: 18759114     Source Type: Journal    
DOI: 10.1002/phar.1309     Document Type: Article

References (38)

1. Upton A, Kirby KA, Carpenter P, Boeckh M, Marr KA,. Invasive aspergillosis following hematopoietic cell transplantation: outcomes and prognostic factors associated with mortality. Clin Infect Dis 2007; 44: 531-40.
2. Neofytos D, Horn D, Anaissie E, et al. Epidemiology and outcome of invasive fungal infection in adult hematopoietic stem cell transplant recipients: analysis of Multicenter Prospective Antifungal Therapy (PATH) Alliance registry. Clin Infect Dis 2009; 48: 265-73.
3. Pongas GN, Lewis RE, Samonis G, Kontoyiannis DP,. Voriconazole-associated zygomycosis: a significant consequence of evolving antifungal prophylaxis and immunosuppression practices? Clin Microbiol Infect 2009; 15 (Suppl 5): 93-7.
4. Nivoix Y, Velten M, Letscher-Bru V, et al. Factors associated with overall and attributable mortality in invasive aspergillosis. Clin Infect Dis 2008; 47: 1176-84.
5. Safdar A,. Immunotherapy for invasive mold disease in severely immunosuppressed patients. Clin Infect Dis 2013; 57: 94-100.
6. Safdar A,. Strategies to enhance immune function in hematopoietic transplantation recipients who have fungal infections. Bone Marrow Transplant 2006; 38: 327-37.
7. Safdar A, Rodriguez GH, Mihu CN, et al. Infections in non-myeloablative hematopoietic stem cell transplantation patients with lymphoid malignancies: spectrum of infections, predictors of outcome and proposed guidelines for fungal infection prevention. Bone Marrow Transplant 2010; 45: 339-47.
8. Stevens DA, Brummer E, Clemons KV,. Interferon-gamma as an antifungal. J Infect Dis 2006; 194: S33-7.
9. Safdar A,. Immunomodulation therapy for invasive aspergillosis: discussion on myeloid growth factors, recombinant cytokines, and antifungal drug immune modulation. Curr Fungal Infect Rep 2010; 4: 1-7.
10. Safdar A, Rodriguez GH, Lichtiger B, et al. Recombinant interferon gamma1b immune enhancement in 20 patients with hematologic malignancies and systemic opportunistic infections treated with donor granulocyte transfusions. Cancer 2006; 106: 2664-71.
11. Seidel MG, Peters C, Wacker A, et al. Randomized phase III study of granulocyte transfusions in neutropenic patients. Bone Marrow Transplant 2008; 42: 679-84.
12. Safdar A, Shelburne S, Evans S, Dickey B,. Inhaled therapeutics for prevention and treatment of pneumonia. Expert Opin Drug Saf 2009; 8: 435-49.
13. Husain S, Capitano B, Corcoran T, et al. Intrapulmonary disposition of amphotericin B after aerosolized delivery of amphotericin B lipid complex (Abelcet; ABLC) in lung transplant recipients. Transplantation 2010; 90: 1215-9.
14. Monforte V, Ussetti P, Gavaldà J, et al. Feasibility, tolerability, and outcomes of nebulized liposomal amphotericin B for Aspergillus infection prevention in lung transplantation. J Heart Lung Transplant 2010; 29: 523-30.
15. Montoya JG, Giraldo LF, Efron B, et al. Infectious complications among 620 consecutive heart transplant patients at Stanford University Medical Center. Clin Infect Dis 2001; 33: 629-40.
16. Palmer SM, Drew RH, Whitehouse JD, et al. Safety of aerosolized amphotericin B lipid complex in lung transplant recipients. Transplantation 2001; 72: 545-8.
17. Palmer SM, Drew RH, Whitehouse JD, et al. Aerosolized liposomal amphotericin B for the prevention of invasive pulmonary aspergillosis during prolonged neutropenia: a randomized, placebo-controlled trial. Clin Infect Dis 2008; 46: 1409-11.
18. Slobbe L, Boersma E, Rijnders BJ,. Tolerability of prophylactic aerosolized liposomal amphotericin-B and impact on pulmonary function: data from a randomized placebo-controlled trial. Pulm Pharmacol Ther 2008; 21: 855-9.
19. Rijnders BJ, Cornelissen JJ, Slobbe L, et al. Aerosolized liposomal amphotericin B for the prevention of invasive pulmonary aspergillosis during prolonged neutropenia: a randomized, placebo-controlled trial. Clin Infect Dis 2008; 46: 1409-11.
20. Schwartz S, Behre G, Heinemann V, et al. Aerosolized amphotericin B inhalations as prophylaxis of invasive Aspergillus infections during prolonged neutropenia: results of a prospective randomized multicenter trial. Blood 1999; 93: 3654-61.
21. Behre GF, Schwartz S, Lenz K, et al. Aerosol amphotericin B inhalations for prevention of invasive pulmonary aspergillosis in neutropenic cancer patients. Ann Hematol 1995; 71: 287-91.
22. Safdar A, O'Brien S, Khouri IF,. Efficacy and feasibility of aerosolized amphotericin B lipid complex therapy in caspofungin breakthrough pulmonary zygomycosis. Bone Marrow Transplant 2004; 34: 467-8.
23. Diot P, Rivoire B, Le Pape A, et al. Deposition of amphotericin B aerosols in pulmonary aspergilloma. Eur Respir J 1995; 8: 1263-8.
24. De Pauw B, Walsh TJ, Donnelly JP, et al. Revised definitions of invasive fungal disease from the European Organization for Research and Treatment of Cancer/Invasive Fungal Infections Cooperative Group and the National Institute of Allergy and Infectious Diseases Mycoses Study Group (EORTC/MSG) Consensus Group. Clin Infect Dis 2008; 46: 1813-21.
25. Greene RE, Schlamm HT, Oestmann JW, et al. Imaging findings in acute invasive pulmonary aspergillosis: clinical significance of the halo sign. Clin Infect Dis 2007; 44: 373-9.
26. Boots RJ, Paterson DL, Allworth AM, Faoagali JL,. Successful treatment of post-influenza pseudomembranous necrotising bronchial aspergillosis with liposomal amphotericin, inhaled amphotericin B, gamma interferon and GM-CSF. Thorax 1999; 54: 1047-9.
27. Drew RH, Dodds Ashley E, Benjamin DK Jr, Duane DR, Palmer SM, Perfect JR,. Comparative safety of amphotericin B lipid complex and amphotericin B deoxycholate as aerosolized antifungal prophylaxis in lung-transplant recipients. Transplantation 2004; 77: 232-7.
28. Borro JM, Solé A, de la Torre M, et al. Efficiency and safety of inhaled amphotericin B lipid complex (Abelcet) in the prophylaxis of invasive fungal infections following lung transplantation. Transplant Proc 2008; 40: 3090-3.
29. Alexander BD, Dodds Ashley ES, Addison RM, Alspaugh JA, Chao NJ, Perfect JR,. Non-comparative evaluation of the safety of aerosolized amphotericin B lipid complex in patients undergoing allogeneic hematopoietic stem cell transplantation. Transpl Infect Dis 2006; 8: 13-20.
30. Koizumi T, Kubo K, Kaneki T, et al. Pharmacokinetic evaluation of amphotericin B in lung tissue: lung lymph distribution after intravenous injection and airspace distribution after aerosolization and inhalation of amphotericin B. Antimicrob Agents Chemother 1998; 42: 1597-600.
31. Schmitt HJ, Bernard EM, Hauser M, Armstrong D,. Aerosol amphotericin B is effective for prophylaxis and therapy in a rat model of pulmonary aspergillosis. Antimicrob Agents Chemother 1988; 32: 1676-9.
32. Cicogna CE, White MH, Bernard EM, et al. Efficacy of prophylactic aerosol amphotericin B lipid complex in a rat model of pulmonary aspergillosis. Antimicrob Agents Chemother 1997; 41: 259-61.
33. Dhand R, Guntur VP,. How best to deliver aerosol medications to mechanically ventilated patients. Clin Chest Med 2008; 29: 277-96.
34. MacIntyre NR, Silver RM, Miller CV, Schuler F, Colman RE,. Aerosol delivery in intubated, mechanically ventilated patients. Crit Care Med 1985; 13: 81-4.
35. American Association for Respiratory Care. Aerosol consensus statement-1991. Respir Care 1991; 36: 916-21.
36. Corcoran TE, Venkataramanan R, Mihelc KM, et al. Aerosol deposition of lipid complex amphotericin-B (Abelcet) in lung transplant recipients. Am J Transplant 2006; 6: 2765-73.
37. Dhand R, Sohal H,. Pulmonary drug delivery system for inhalation therapy in mechanically ventilated patients. Expert Rev Med Devices 2008; 5: 9-18.
38. Watts AB, McConville JT, Williams RO,. Current therapies and technological advances in aqueous aerosol drug delivery. Drug Dev Ind Pharm 2008; 34: 913-22.